These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 28903344)

  • 81. Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer.
    Villarroel MC; Rajeshkumar NV; Garrido-Laguna I; De Jesus-Acosta A; Jones S; Maitra A; Hruban RH; Eshleman JR; Klein A; Laheru D; Donehower R; Hidalgo M
    Mol Cancer Ther; 2011 Jan; 10(1):3-8. PubMed ID: 21135251
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy.
    Barretina J; Taylor BS; Banerji S; Ramos AH; Lagos-Quintana M; Decarolis PL; Shah K; Socci ND; Weir BA; Ho A; Chiang DY; Reva B; Mermel CH; Getz G; Antipin Y; Beroukhim R; Major JE; Hatton C; Nicoletti R; Hanna M; Sharpe T; Fennell TJ; Cibulskis K; Onofrio RC; Saito T; Shukla N; Lau C; Nelander S; Silver SJ; Sougnez C; Viale A; Winckler W; Maki RG; Garraway LA; Lash A; Greulich H; Root DE; Sellers WR; Schwartz GK; Antonescu CR; Lander ES; Varmus HE; Ladanyi M; Sander C; Meyerson M; Singer S
    Nat Genet; 2010 Aug; 42(8):715-21. PubMed ID: 20601955
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib.
    O'Brien NA; Browne BC; Chow L; Wang Y; Ginther C; Arboleda J; Duffy MJ; Crown J; O'Donovan N; Slamon DJ
    Mol Cancer Ther; 2010 Jun; 9(6):1489-502. PubMed ID: 20501798
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.
    Fichtner I; Rolff J; Soong R; Hoffmann J; Hammer S; Sommer A; Becker M; Merk J
    Clin Cancer Res; 2008 Oct; 14(20):6456-68. PubMed ID: 18927285
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Metastatic myxoid liposarcomas: imaging and histopathologic findings.
    Sheah K; Ouellette HA; Torriani M; Nielsen GP; Kattapuram S; Bredella MA
    Skeletal Radiol; 2008 Mar; 37(3):251-8. PubMed ID: 18097662
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study.
    Grosso F; Jones RL; Demetri GD; Judson IR; Blay JY; Le Cesne A; Sanfilippo R; Casieri P; Collini P; Dileo P; Spreafico C; Stacchiotti S; Tamborini E; Tercero JC; Jimeno J; D'Incalci M; Gronchi A; Fletcher JA; Pilotti S; Casali PG
    Lancet Oncol; 2007 Jul; 8(7):595-602. PubMed ID: 17586092
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Myxoid liposarcoma FUS-DDIT3 fusion oncogene induces C/EBP beta-mediated interleukin 6 expression.
    Göransson M; Elias E; Ståhlberg A; Olofsson A; Andersson C; Aman P
    Int J Cancer; 2005 Jul; 115(4):556-60. PubMed ID: 15688424
    [TBL] [Abstract][Full Text] [Related]  

  • 88. TOR signaling in mammals.
    Carrera AC
    J Cell Sci; 2004 Sep; 117(Pt 20):4615-6. PubMed ID: 15371520
    [No Abstract]   [Full Text] [Related]  

  • 89. The chimeric FUS/TLS-CHOP fusion protein specifically induces liposarcomas in transgenic mice.
    Pérez-Losada J; Pintado B; Gutiérrez-Adán A; Flores T; Bañares-González B; del Campo JC; Martín-Martín JF; Battaner E; Sánchez-García I
    Oncogene; 2000 May; 19(20):2413-22. PubMed ID: 10828883
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
    Van Glabbeke M; van Oosterom AT; Oosterhuis JW; Mouridsen H; Crowther D; Somers R; Verweij J; Santoro A; Buesa J; Tursz T
    J Clin Oncol; 1999 Jan; 17(1):150-7. PubMed ID: 10458228
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Establishing a patient-derived xenograft model of human myxoid and round-cell liposarcoma.
    Qi Y; Hu Y; Yang H; Zhuang R; Hou Y; Tong H; Feng Y; Huang Y; Jiang Q; Ji Q; Gu Q; Zhang Z; Tang X; Lu W; Zhou Y
    Oncotarget; 2017 Aug; 8(33):54320-54330. PubMed ID: 28903344
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Myxoid liposarcoma and the mammalian target of rapamycin pathway.
    Sanfilippo R; Dei Tos AP; Casali PG
    Curr Opin Oncol; 2013 Jul; 25(4):379-83. PubMed ID: 23673410
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Myxoid Liposarcoma With Skeletal Metastases: Pathophysiology and Imaging Characteristics.
    Mujtaba B; Wang F; Taher A; Aslam R; Madewell JE; Nassar S
    Curr Probl Diagn Radiol; 2021; 50(1):66-73. PubMed ID: 31813645
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Myxoid and round cell liposarcoma: a spectrum of myxoid adipocytic neoplasia.
    Orvieto E; Furlanetto A; Laurino L; Dei Tos AP
    Semin Diagn Pathol; 2001 Nov; 18(4):267-73. PubMed ID: 11757867
    [TBL] [Abstract][Full Text] [Related]  

  • 95. The Essential Factors of Establishing Patient-derived Tumor Model.
    Chen C; Lin W; Huang Y; Chen X; Wang H; Teng L
    J Cancer; 2021; 12(1):28-37. PubMed ID: 33391400
    [TBL] [Abstract][Full Text] [Related]  

  • 96.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 97.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 98.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 99.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 5.